GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo Inc (OTCPK:NDOI) » Definitions » Debt-to-EBITDA

Endo (NDOI) Debt-to-EBITDA : -3.20 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Endo Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Endo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $21 Mil. Endo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2,446 Mil. Endo's annualized EBITDA for the quarter that ended in Sep. 2024 was $-771 Mil. Endo's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -3.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Endo's Debt-to-EBITDA or its related term are showing as below:

NDOI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.4
Current: 0.4

During the past 0 years, the highest Debt-to-EBITDA Ratio of Endo was 0.40. The lowest was 0.00. And the median was 0.00.

NDOI's Debt-to-EBITDA is ranked better than
74.77% of 662 companies
in the Drug Manufacturers industry
Industry Median: 1.595 vs NDOI: 0.40

Endo Debt-to-EBITDA Historical Data

The historical data trend for Endo's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo Debt-to-EBITDA Chart

Endo Annual Data
Trend
Debt-to-EBITDA

Endo Quarterly Data
Jun23 Sep23 Apr24 Sep24
Debt-to-EBITDA - - - -3.20

Competitive Comparison of Endo's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Endo's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endo's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Endo's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Endo's Debt-to-EBITDA falls into.



Endo Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Endo's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Endo's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(20.874 + 2446.103) / -770.756
=-3.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Endo  (OTCPK:NDOI) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Endo Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Endo's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Endo Business Description

Traded in Other Exchanges
N/A
Address
1400 Atwater Drive, Malvern, PA, USA, 19355
Endo Inc is a diversified specialty pharmaceutical company that develops, manufactures, markets and sells a broad portfolio of pharmaceutical products across four reportable segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.